HC Wainwright & Co. Maintains Buy on Purple Biotech, Lowers Price Target to $17

Benzinga · 1d ago
HC Wainwright & Co. analyst Emily Bodnar maintains Purple Biotech (NASDAQ:PPBT) with a Buy and lowers the price target from $30 to $17.